Tetraphase Pharmaceuticals, Inc. (TTPH)

[iDeVos]

XERAVA
o Tetracycline “Fluorocycline”
- C7 and C9 help avoid Tetracycline resistance
- Higher potency than tigecycline for GPC, GNR, anaerobes
o Indication: cIAI, not cUTI
o Susceptible pathogens: Gram positive, gram negative, anaerobes
o Warnings:
- Tooth discoloration, enamel hypoplasia
- Inhibition of bone growth
- CDI
o AE:
- Infusion site reactions, N/V
o Interactions
- CYP3A4
o Dosing 1mg/kg IV q12.
- Modified to q24h for severe hepatic impairment (after 24h @ q12h)
o Unique Aspects
- IV only
- Infusion site reactions and nausea
- High potency, reduced tetracycline resistance
- Option for ESBL
- Tetracycline warnings regarding pregnancy and fetal exposure
- Broad spectrum including anaerobes, MRSA, VRE.
o 34% to urine unchanged, 47% to feces unchanged
o Non-inferior to ertapenem in cIAI
o cUTI studies did not meet efficacy endpoints